The Chronic Refractory Gout (CRG) Market is growing due to the rising prevalence of chronic gout, uncontrolled hyperuricemia, and increasing demand for effective urate-lowering therapies. Growing awareness of treatment-resistant gout and the development of pipeline candidates such as NASP (SEL-212),